Market News AIOpen the app

ARCT stock news · Arcturus Therapeutics Ltd.

Stories about Arcturus Therapeutics Ltd. (ARCT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ARCT

Follow Arcturus Therapeutics Ltd. (ARCT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARCT
Free on the App Store and Google Play, or on the web.
  1. Oct 31, 2026, 10:16 AM ET · Market

    ARK Invest has bought more shares of Pacific Biosciences and other biotech companies.

    Neutral

    Arcturus Therapeutics was named among the companies ARK added to its holdings. The report gives no new company results or plans, so its business outlook is unchanged.

  2. Oct 14, 2026, 6:17 AM ET · Results

    Arcturus Therapeutics shares details from its earnings call for the second quarter of 2026.

    Neutral

    Arcturus reported progress in rare-disease studies and regained vaccine rights, but revenue fell after CSL's exit and trial results remain pending. These facts leave its outlook unchanged.

  3. Sep 23, 2026, 4:19 PM ET · Trial

    Arcturus Therapeutics shares new Phase 2 clinical data and updates on its mRNA delivery system.

    Neutral

    Arcturus presented Phase 2 data and a platform update, but the 8-K only furnishes the presentation and press release without detailed trial numbers.